Peregrine Capital Management LLC Blueprint Medicines Corp Transaction History

Peregrine Capital Management LLC

$3.18 Billion
Q3 2024

A detailed history of Peregrine Capital Management LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Peregrine Capital Management LLC holds 97,051 shares of BPMC stock, worth $8.75 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares

97,051

Previous 79,560 21.98%

Holding current value

$8.75 Million

Previous $8.57 Million 4.65%

% of portfolio

0.28%

Previous 0.26%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	BUY	$84.1 - $120.5 $1.47 Million - $2.11 Million	17,491 Added 21.98%	97,051 $8.97 Million
Q2 2024 Jul 29, 2024	SELL	$85.18 - $108.78 $1.19 Million - $1.53 Million	-14,023 Reduced 14.98%	79,560 $8.57 Million
Q1 2024 Apr 26, 2024	BUY	$73.17 - $99.79 $132,437 - $180,619	1,810 Added 1.97%	93,583 $8.88 Million
Q4 2023 Jan 26, 2024	SELL	$43.96 - $92.84 $2.41 Million - $5.1 Million	-54,890 Reduced 37.43%	91,773 $8.47 Million
Q3 2023 Oct 19, 2023	BUY	$46.9 - $66.0 $144,170 - $202,884	3,074 Added 2.14%	146,663 $7.37 Million
Q2 2023 Jul 26, 2023	SELL	$42.2 - $66.37 $675,833 - $1.06 Million	-16,015 Reduced 10.03%	143,589 $9.07 Million
Q1 2023 Apr 26, 2023	BUY	$37.97 - $50.0 $1.19 Million - $1.57 Million	31,362 Added 24.46%	159,604 $7.18 Million
Q4 2022 Jan 10, 2023	BUY	$41.06 - $66.48 $655,071 - $1.06 Million	15,954 Added 14.21%	128,242 $5.62 Million
Q3 2022 Oct 26, 2022	SELL	$49.93 - $77.7 $1.02 Million - $1.58 Million	-20,333 Reduced 15.33%	112,288 $7.4 Million
Q2 2022 Jul 20, 2022	BUY	$45.23 - $70.15 $260,208 - $403,572	5,753 Added 4.53%	132,621 $6.7 Million
Q1 2022 Apr 27, 2022	BUY	$54.1 - $110.08 $173,065 - $352,145	3,199 Added 2.59%	126,868 $8.1 Million
Q4 2021 Jan 31, 2022	BUY	$94.25 - $115.99 $329,875 - $405,965	3,500 Added 2.91%	123,669 $13.2 Million
Q3 2021 Nov 02, 2021	SELL	$80.98 - $109.47 $3.19 Million - $4.31 Million	-39,414 Reduced 24.7%	120,169 $12.4 Million
Q2 2021 Aug 03, 2021	BUY	$82.78 - $101.0 $701,229 - $855,571	8,471 Added 5.61%	159,583 $14 Million
Q1 2021 May 11, 2021	SELL	$90.71 - $108.28 $1.91 Million - $2.28 Million	-21,086 Reduced 12.25%	151,112 $14.7 Million
Q4 2020 Jan 19, 2021	SELL	$92.08 - $124.48 $1.44 Million - $1.95 Million	-15,651 Reduced 8.33%	172,198 $19.3 Million
Q3 2020 Oct 20, 2020	BUY	$66.45 - $92.7 $1.18 Million - $1.64 Million	17,742 Added 10.43%	187,849 $17.4 Million
Q2 2020 Jul 30, 2020	SELL	$57.09 - $79.27 $1.62 Million - $2.25 Million	-28,360 Reduced 14.29%	170,107 $13.3 Million
Q1 2020 Apr 17, 2020	BUY	$48.11 - $82.22 $9.55 Million - $16.3 Million	198,467 New	198,467 $11.6 Million

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.38B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peregrine Capital Management LLC with notifications on news.

Account

Peregrine Capital Management LLC Blueprint Medicines Corp Transaction History